Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate

Vox Sanguinis

Volumn 104, Issue 1, 2013, Pages 1-6

  Burnouf, T ^a,b   Chou, M L ^b   Cheng, L H ^c   Li, Z R ^c   Wu, Y W ^b   El Ekiaby, M ^d   Tsai, K H ^c  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d Shabrawishi Hospital Blood Bank   (Egypt)

Author keywords

Cryoprecipitate; Dengue; Plasma; Solvent detergent

Indexed keywords

DETERGENT; SOLVENT; TRIBUTYL PHOSPHATE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYOPRECIPITATE; CULTURE MEDIUM; DENGUE VIRUS; FOCUS FORMING ASSAY; HUMAN; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROCEDURES; VERO CELL; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS TITRATION;

ANIMALS; BLOOD PRESERVATION; BLOOD SAFETY; BLOOD TRANSFUSION; CERCOPITHECUS AETHIOPS; COMPLEMENT SYSTEM PROTEINS; CULICIDAE; DENGUE; DENGUE VIRUS; DETERGENTS; FACTOR VIII; FIBRINOGEN; HUMANS; OCTOXYNOL; ORGANOPHOSPHATES; PLASMA; SOLVENTS; TIME FACTORS; VERO CELLS; VIRUS INACTIVATION;

EID: 84871288798     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01621.x     Document Type: Article

References (34)

1. Kuhn RJ, Zhang W, Rossmann MG, et al.: Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108:717-725.
2. Bennett SN, Holmes EC, Chirivella M, et al.: Selection-driven evolution of emergent dengue virus. Mol Biol Evol 2003; 20:1650-1658.
3. Tomashek KM, Margolis HS: Dengue: a potential transfusion-transmitted disease. Transfusion 2011; 51:1654-1660.
4. Khasnis AA, Nettleman MD: Global warming and infectious disease. Arch Med Res 2005; 36:689-696.
5. Linnen JM, Vinelli E, Sabino EC, et al.: Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion 2008; 48:1355-1362.
6. Mohammed H, Linnen JM, Munoz-Jordan JL, et al.: Dengue virus in blood donations, Puerto Rico, 2005. Transfusion 2008; 48:1348-1354.
7. Stramer SL, Linnen JM, Carrick JM, et al.: Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012. DOI: 10.1111/j.1537-2995.2012.03566.x.
8. Wilder-Smith A, Chen LH, Massad E, et al.: Threat of dengue to blood safety in dengue-endemic countries. Emerg Infect Dis 2009; 15:8-11.
9. Teo D, Ng LC, Lam S: Is dengue a threat to the blood supply?Transfus Med 2009; 19:66-77.
10. Tambyah PA, Koay ES, Poon ML, et al.: Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008; 359:1526-1527.
11. Seed CR, Kiely P, Hyland CA, et al.: The risk of dengue transmission by blood during a 2004 outbreak in Cairns, Australia. Transfusion 2009; 49:1482-1487.
12. Xie YW, Chan PK, Szeto CK, et al.: Clearance of dengue virus in the plasma-derived therapeutic proteins. Transfusion 2008; 48:1342-1347.
13. Kreil TR: West Nile virus: recent experience with the model virus approach. Dev Biol (Basel) 2004; 118:101-105.
14. Kreil TR, Berting A, Kistner O, et al.: West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43:1023-1028.
15. Burnouf T, Caron C, Radosevich M, et al.: Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. Haemophilia 2008; 14:956-962.
16. WHO: Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. Geneva, WHO, 2003. Available at: http://www.WHO.int/bloodproducts (last accessed May 30, 2012).
17. Horowitz B, Bonomo R, Prince AM, et al.: Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79:826-831.
18. Gubler DJ: Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100-103.
19. Halstead SB: Dengue virus-mosquito interactions. Annu Rev Entomol 2008; 53:273-291.
20. Chuang VW, Wong TY, Leung YH, et al.: Review of dengue fever cases in Hong Kong during 1998 to 2005. Hong Kong Med J 2008; 14:170-177.
21. Petersen LR, Tomashek KM, Biggerstaff BJ: Estimated prevalence of dengue viremia in Puerto Rican blood donations, 1995 through 2010. Transfusion 2012. DOI: 10.1111/j.1537-2995.2011.03529.x.
22. Chuansumrit A, Isarangkura P, Chantanakajornfung A, et al.: The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. J Med Assoc Thai 1999; 82(Suppl 1):S69-S73.
23. Srivastava A: Factor replacement for haemophilia--should cryoprecipitate be used?Haemophilia 1999; 5:301-305.
24. Burnouf T, Goubran H, Radosevich M, et al.: Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries. ISBT Sci Ser 2007; 2:121-128.
25. Sorensen B, Bevan D: A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149:834-843.
26. Motta M, Del Vecchio A, Radicioni M: Clinical use of fresh-frozen plasma and cryoprecipitate in neonatal intensive care unit. J Matern Fetal Neonatal Med 2011; 24(Suppl 1):129-131.
27. El-Ekiaby M, Sayed MA, Caron C, et al.: Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 2010; 20:48-61.
28. Avirutnan P, Hauhart RE, Marovich MA, et al.: Complement-mediated neutralization of dengue virus requires mannose-binding lectin. MBio 2011; 2:e00276-11.
29. CPMP: Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (revised). London: European Agency for the Evaluation of Medicinal Products (EMEA), 1996, CPMP/BWP/CPMP/5136/03. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003684.pdf (last accessed May 30, 2012).
30. Moake J, Chintagumpala M, Turner N, et al.: Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84:490-497.
31. Roberts PL, Lloyd D, Marshall PJ: Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20. Biologicals 2009; 37:26-31.
32. Dichtelmuller HO, Biesert L, Fabbrizzi F, et al.: Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009; 49:1931-1943.
33. Leydold SM, Farcet MR, Kindermann J, et al.: Chikungunya virus and the safety of plasma products. Transfusion 2012. DOI: 10.1111/j.1537-2995.2012.03565.x.
34. El-Ekiaby M, Goubran HA, Radosevich M, et al.: Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. Haemophilia 2011; 17:e884-e888.